9 Non-Small Cell Lung Cancer Clinical Trials in Phoenix, AZ (2026)

Q: How do I join a clinical trial in Phoenix?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you.

Recruiting Non-Small Cell Lung Cancer Studies in Phoenix

NCT03851445Recruiting

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to ...

Phoenix, AZPHASE210,000 participantsSWOG Cancer Research Network

View Study Details

NCT07222566Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults w...

Phoenix, AZPHASE31,410 participantsPfizer

View Study Details

NCT04267848Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by...

Phoenix, AZPHASE31,210 participantsNational Cancer Institute (NCI)

View Study Details

NCT04928846Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues...

Phoenix, AZPHASE3768 participantsAbbVie

View Study Details

NCT07063745Recruiting

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus p...

Phoenix, AZPHASE2590 participantsBristol-Myers Squibb

View Study Details

NCT05624996Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by ...

Phoenix, AZPHASE3474 participantsNRG Oncology

View Study Details

NCT06686771Recruiting

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study ...

Phoenix, AZPHASE3320 participantsCanadian Cancer Trials Group

View Study Details

NCT07277413Recruiting

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with met...

Phoenix, AZPHASE1260 participantsIDEAYA Biosciences

View Study Details

NCT05642572Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread fr...

Phoenix, AZPHASE266 participantsSWOG Cancer Research Network

View Study Details

About Non-Small Cell Lung Cancer Clinical Trials in Phoenix

Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Subtypes include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Treatment has been transformed by targeted therapies and immunotherapy based on specific genetic markers.

There are currently 9 non-small cell lung cancer clinical trials recruiting participants in Phoenix, AZ. These studies are seeking a combined 15,098 participants. Research is being sponsored by SWOG Cancer Research Network, Pfizer, National Cancer Institute (NCI) and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Non-Small Cell Lung Cancer Clinical Trials in Phoenix — FAQ

Are there non-small cell lung cancer clinical trials in Phoenix?

Yes, there are 9 non-small cell lung cancer clinical trials currently recruiting in Phoenix, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What non-small cell lung cancer treatments are being tested?

The 9 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for non-small cell lung cancer.

Data updated October 17, 2026 from ClinicalTrials.gov